Article
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.
Cancer research - 15 Jan 2013
Fleming Nicholas I, Jorissen Robert N, Mouradov Dmitri, Christie Michael, Sakthianandeswaren Anuratha, Palmieri Michelle, Day Fiona, Li Shan, Tsui Cary, Lipton Lara, Desai Jayesh, Jones Ian T, McLaughlin Stephen, Ward Robyn L, Hawkins Nicholas J, Ruszkiewicz Andrew R, Moore James, Zhu Hong-Jian, Mariadason John M, Burgess Antony W, Busam Dana, Zhao Qi, Strausberg Robert L, Gibbs Peter, Sieber Oliver M
Abstract excerpt
Activation of the canonical TGF-β signaling pathway provides growth inhibitory signals in the normal intestinal epithelium. Colorectal cancers (CRCs) frequently harbor somatic mutations in the pathway members TGFBR2 and SMAD4, but to what extent mutations in SMAD2 or SMAD3 contribute to tumorigenesis is unclear. A cohort of 744 primary CRCs and 36 CRC cell lines were sequenced for SMAD4, SMAD2, and SMAD3 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.